Fukushima-shi, Japan
Fukushima-shi, Japan

Time filter

Source Type

Patent
Riken, Animal Allergy Clinical Laboratories Inc. and Nippon Zenyaku Kogyo Co. | Date: 2017-04-19

The present invention provides a synthetic peptide capable of inducing an antibody to an autoantigen, and specifically, provides: a multiplexed same type-antigenic peptide comprising a dendritic core and B-cell recognition peptides, wherein the multiplexed same type-antigenic peptide comprises 4 to 8 B-cell recognition peptides of the same type that are bound to the terminal ends of the dendritic core directly or via a spacer, and each B-cell recognition peptide is bound to the terminal end of the dendritic core directly or via a spacer; an antibody production-inducing agent comprising the peptides; and a method for producing the peptide.


Patent
Nippon Zenyaku Kogyo Co. | Date: 2017-05-17

The object of the present invention is to provide an anti-canine PD-1 antibody or an anti-canine PD-L1 antibody, an agent for inhibiting binding between a canine PD-1 and a canine PD-L1 containing such an antibody, a method for inhibiting binding between a canine PD-1 and a canine PD-L1 comprising using such an antibody, and a gene encoding such an antibody. An anti-canine PD-1 antibody that specifically binds to a canine PD-1 consisting of the amino acid sequence set forth in SEQ ID NO: 1 and an anti-canine PD-L1 antibody that specifically binds to a canine PD-L1 consisting of the amino acid sequence set forth in SEQ ID NO: 6 are produced. An agent for inhibiting binding between a canine PD-1 and a canine PD-L1 containing such an antibody is also produced.


Patent
Riken, Animal Allergy Clinical Laboratories Inc. and Nippon Zenyaku Kogyo Co. | Date: 2015-06-11

The present invention provides a synthetic peptide capable of inducing an antibody to an autoantigen, and specifically, provides: a multiplexed same type-antigenic peptide having a dendritic core and B-cell recognition peptides, wherein the multiplexed same type-antigenic peptide comprises 4 to 8 B-cell recognition peptides of the same type that are bound to the terminal ends of the dendritic core directly or via a spacer, and each B-cell recognition peptide is bound to the terminal end of the dendritic core directly or via a spacer; an antibody production-inducing agent having the peptides; and a method for producing the peptide.


Patent
Nippon Zenyaku Kogyo Co. | Date: 2015-07-08

The object of the present invention is to provide an anti-canine PD-1 antibody or an anti-canine PD-L1 antibody, an agent for inhibiting binding between a canine PD-1 and a canine PD-L1 containing such an antibody, a method for inhibiting binding between a canine PD-1 and a canine PD-L1 comprising using such an antibody, and a gene encoding such an antibody. An anti-canine PD-1 antibody that specifically binds to a canine PD-1 consisting of the amino acid sequence set forth in SEQ ID NO: 1 and an anti-canine PD-L1 antibody that specifically binds to a canine PD-L1 consisting of the amino acid sequence set forth in SEQ ID NO: 6 are produced. An agent for inhibiting binding between a canine PD-1 and a canine PD-L1 containing such an antibody is also produced.


Patent
Osaka University and Nippon Zenyaku Kogyo Co. | Date: 2014-06-04

This invention provides a method of preparing a -hematin crystal comprising a step of heating, the -hematin crystal obtained by such method, and a vaccine adjuvant composition containing the -hematin crystal. The -hematin crystal has a needle-like morphology, it has an average particle size of 0.6 to 1.2 m, and it exhibits main peaks characteristics for angles of diffraction (2) of 7.4, 12.2, 21.6, and 24.1 in an X-ray diffraction pattern obtained by powder X-ray diffractometry with CuK rays (with each peak including a plus-minus 0.2 diffraction angle).


Patent
Nippon Zenyaku Kogyo Co. | Date: 2013-10-14

A safe and efficient recombinant mite allergen is provided as a therapeutic agent or a diagnostic agent for mite allergic diseases, which contains no anaphylaxis-inducing impurities. The following recombinant protein (a) or (b) is provided: (a) a protein comprising the amino acid sequence represented by SEQ ID NO: 2 or 35; or (b) a protein comprising an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO: 2 or 35 by deletion, substitution, or addition of one or several amino acids and having mite allergen activity.


Patent
Kazusa DNA Research Institute, Nippon Zenyaku Kogyo Co. and Animal Allergy Clinical Laboratories Inc. | Date: 2014-03-17

Problem to be Solved: The present invention is intended to provide a polynucleotide encoding the light-chain variable region and the heavy-chain variable region of an anti-dog IgE antibody; and an anti-dog IgE antibody containing these variable regions. Solution: The present invention is DNA encoding a heavy-chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 2 or 6 and DNA encoding a light-chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 4 or 8, and an anti-dog IgE monoclonal antibody which binds to dog IgE, containing these variable regions or a functional fragment thereof which binds to dog IgE.


Patent
Nippon Zenyaku Kogyo Co. | Date: 2015-04-22

It is intended to provide an IgE peptide vaccine that can be used in the prevention or treatment of allergic diseases in animals other than mice, such as humans or dogs. The present invention provides a peptide consisting of (i) the amino acid sequence represented by SEQ ID NO: 28, or (ii) an amino acid sequence consisting of at least 10 consecutive amino acids in the amino acid sequence represented by SEQ ID NO: 28, wherein the peptide, when administered to an animal, is capable of specifically binding to a CH3 region in an IgE antibody of the animal and thereby blocking the binding of the IgE antibody to an IgE receptor.


Patent
Kazusa DNA Research Institute, Animal Allergy Clinical Laboratories Inc. and Nippon Zenyaku Kogyo Co. | Date: 2016-01-27

Problem to be Solved: The present invention is intended to provide a polynucleotide encoding the light-chain variable region and the heavy-chain variable region of an anti-dog IgE antibody; and an anti-dog IgE antibody containing these variable regions. Solution: The present invention is DNA encoding a heavy-chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 2 or 6 and DNA encoding a light-chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 4 or 8, and an anti-dog IgE monoclonal antibody which binds to dog IgE, containing these variable regions or a functional fragment thereof which binds to dog IgE.


Patent
Osaka University and Nippon Zenyaku Kogyo Co. | Date: 2016-04-13

This invention provides a method of preparing a -hematin crystal comprising a step of heating, the -hematin crystal obtained by such method, and a vaccine adjuvant composition containing the -hematin crystal. The -hematin crystal has a needle-like morphology, it has an average particle size of 0.6 to 1.2 m, and it exhibits main peaks characteristics for angles of diffraction (2) of 7.4, 12.2, 21.6, and 24.1 in an X-ray diffraction pattern obtained by powder X-ray diffractometry with Cu-K rays (with each peak including a plus-minus 0.2 diffraction angle).

Loading Nippon Zenyaku Kogyo Co. collaborators
Loading Nippon Zenyaku Kogyo Co. collaborators